AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04433637 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video group
Description: Music with motivational video experimental group, pregnant women were provided with fruit juice and cake, and it was expected that half an hour would pass after feeding to get NST. During this waiting period, the researchers were informed about the development and changes in the body and the fetus specific to the gestational week and NST. Later, NST was applied, and during the procedure, the pregnant women were watched with music that provides relaxation with the video regarding the fetal development appropriate for the gestational week and changes in the mother.
Study NCT03640325 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PRISM (Promoting Resilience in Stress Management)
Description: Manualized Skills-Training Program targeting resilience resources: stress-management, goal-setting, cognitive reframing, and meaning-making
Study NCT04785534 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical Evaluation
Description: Undergo clinical evaluation
Study NCT04785534 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT04785534 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liver Ultrasonographic Elastography
Description: Undergo fibroscan
Study NCT04785534 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Complete survey
Study NCT03415594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FE203799 GLP-2 analogue
Description: FE203799 5 mg subQ once weekly
Study NCT03415594 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: FE203799 Placebo GLP-2 analogue
Description: Placebo subQ once weekly
Study NCT03415594 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: FE203799 GLP-2 analogue
Description: FE203799 10 mg subQ once weekly
Study NCT01575639 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral prednisolone
Description: Dose will be different in the two groups. the high dose group will receive 4 mg/kg/day. The usual dose group will receive 2 mg/kg/day
Study NCT01575639 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral prednisolone
Description: Dose will be different in the two groups. the high dose group will receive 4 mg/kg/day. The usual dose group will receive 2 mg/kg/day
Study NCT03261739 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04216511 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Tumor autoantibody detection
Description: Level of a set of autoantibodies potentially relative with lung cancer will be tested for each of the participants.
Study NCT02482428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Investigational Treatment
Description: Applied twice daily for up to 12 weeks
Study NCT02482428 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Investigational Treatment
Description: Applied twice daily for up to 12 weeks
Study NCT02482428 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aldara
Description: Applied 3 times a week for 16 weeks
Study NCT01238991 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ACC-001
Description: IM injection, dose of 3 micrograms, at Day 1, month 6, 12 and 18
Study NCT01238991 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ACC-001
Description: IM injection, dose of 10 micrograms, at Day 1, month 6, 12 and 18
Study NCT01238991 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ACC-001
Description: IM injection, dose of 30 micrograms, at Day 1, month 6, 12 and 18
Study NCT03051880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Repair Control EGF®
Description: A Split face study was done. Patients applied 1 finger tip unit of EGF cream on one side of face, twice a day for 8 weeks. Also, to evaluate the preventive effect of paronychia, patients applied same cream on the finger tips of one side hand, twice a day for 8 weeks.~EGF cream(Repair Control EGF®) containing 10 ppm of rhEGF was prepared at D.N. Co., Ltd. (Seoul, South Korea)
Study NCT03051880 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cream without rhEGF
Description: A Split face study was done. Patients applied 1 finger tip unit of cream on the other side of face, twice a day for 8 weeks. Patients applied same cream on the finger tips of the other side hand, twice a day for 8 weeks.~Placebo cream was prepared at at D.N. Co., Ltd. (Seoul, South Korea), consisted of same ingredient with EGF cream except rhEGF
Study NCT00617084 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Medtronic Endeavor Resolute
Description: Medtronic Endeavor Resolute
Study NCT00617084 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Abbott Xience V
Description: Abbott Xience V
Study NCT00042952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesylate
Description: Given orally
Study NCT00042952 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo surgical resection
Study NCT04080349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dinoprostone 3 mg
Description: 1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia \& Upjohn, Puurs, Belgium) inserted by the study nurse 3 hours before IUD insertion.
Study NCT04080349 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol 200Mcg Tab
Description: 1 vaginal tablet of misoprostol (200 mcg) (Misotac®; Sigma Pharma, SAE, Egypt) inserted by the study nurse 3 hours before IUD insertion.
Study NCT04080349 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: one tablet of placebo inserted by the study nurse 3 hours before IUD insertion
Study NCT03271944 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: CO2 Laser Treatment
Description: Fractional handpiece with CO2 laser: Fractional Ablative laser Treatment of Vulvovaginal Atrophy
Study NCT02401776 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Monster Energy Drink
Description: Small Dose of Monster energy drink. This will be given at a dose of 2mg caffeine/kg body weight (equivalent to approximately one 16 ounce can of monster energy drink for a person weighing 75 kg).
Study NCT02401776 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Monster Energy Drink
Description: Small Dose of Monster energy drink. This will be given at a dose of 2mg caffeine/kg body weight (equivalent to approximately one 16 ounce can of monster energy drink for a person weighing 75 kg).
Study NCT02401776 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Monster energy drink
Description: Medium Dose of Monster Energy Drink. This will be given at a dose of 3 mg caffeine/kg body weight (equivalent to approximately one 24 ounce can of monster energy drink for a person weighing 75 kg).
Study NCT02401776 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Monster energy drink
Description: Medium Dose of Monster Energy Drink. This will be given at a dose of 3 mg caffeine/kg body weight (equivalent to approximately one 24 ounce can of monster energy drink for a person weighing 75 kg).
Study NCT02401776 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Monster Energy Drink
Description: Monster energy drink. This will be given at a dose of 3mg caffeine/kg body weight (equivalent to approximately one 24 ounce can of monster energy drink for a person weighing 75 kg).
Study NCT02401776 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Monster Energy Drink
Description: Monster energy drink. This will be given at a dose of 3mg caffeine/kg body weight (equivalent to approximately one 24 ounce can of monster energy drink for a person weighing 75 kg).
Study NCT02401776 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Coffee
Description: Coffee. This will be given at a dose of 2mg caffeine/kg body weight (equivalent to approximately one 8 ounce cup of coffee drink for a person weighing 75 kg).
Study NCT02401776 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Coffee
Description: Coffee. This will be given at a dose of 2mg caffeine/kg body weight (equivalent to approximately one 8 ounce cup of coffee drink for a person weighing 75 kg).
Study NCT00042952 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00778297 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccination with FluvalAB FL-K-004 trivalent flu vaccine
Description: Treatment: 6 μg HA/strain/dos of FluvalAB FL-K-004 trivalent influenza vaccine will be administered once (at Day 0).
Study NCT00778297 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Vaccination with FluvalAB trivalent influenza vaccine
Description: Treatment: 15 μg HA/strain/dos of FluvalAB trivalent influenza vaccine will be administered once (at Day 0).
Study NCT02483793 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamsulosin
Study NCT02483793 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxybutynin
Study NCT03420755 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mothers and Babies 1-on-1
Description: MB 1-on-1 is a 12-session intervention divided into five modules. An introductory 2-session module establishes key concepts related to stress, monitoring of one's mood, and ways in which one's mood influences one's internal thoughts and external environment; three 3-session modules correspond with key cognitive-behavioral elements: pleasant activities, thoughts, and social support/contact with others; a 1-session summary reviews content and identifies areas for future use of MB skills. Throughout MB, mood management skills are integrated using psycho-educational activities that encourage participants to understand connections between their mood and their activities, thoughts, and contacts with others.
Study NCT03420755 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mothers and Babies Plus Text
Description: MB 1-on-1 along with text enhancements, both in English and Spanish. These texts focus on: a) skill reinforcement (e.g., Some thoughts just come to us, but we can make a conscious effort to think of positive thoughts.); b) homework reminders (e.g., What pleasant activity will you try today?), and c) self-monitoring (e.g., On a scale of 1-9, how would you rate your mood?). These texts will be linked with the 12 MB sessions. Specifically, after completing each in-person session, 3 texts will be sent by a home visitor to her client; one text will focus on skill reinforcement, one will be a homework reminder, and one will focus on self-monitoring.
Study NCT00956007 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: intravenously
Study NCT00956007 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: intensity-modulated radiation therapy
Description: daily fractions
Study NCT00956007 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intensity-modulated radiation therapy
Description: daily fractions
Study NCT03203811 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTI-2088
Description: 3 dose levels
Study NCT00488566 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: GSK drug
Description: GSK drug
Study NCT03203811 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo oral tablet
Study NCT00711048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1386
Description: oral, single dose
Study NCT00711048 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral solution, single dose
Study NCT03195218 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HRME examination
Description: HRME will capture images from all areas considered abnormal by VIA and/or colposcopy. In addition, all four quadrants will be probed with HRME to ensure that any non-acetowhite lesions are also observed
Study NCT03865433 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: Sub-symptom threshold aerobic exercise at a dose of 30 minutes per day, five days per week.
Study NCT03865433 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo/Stretching
Description: A detailed, progressive stretching program to be performed for approximately 20-30 minutes per day, five days per week
Study NCT03629665 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intensive Language-Action Therapy (ILAT)
Description: ILAT includes communicative language games played in an interactive small-group setting. Three persons with aphasia and one therapist sit around a table and have picture cards in front of them. The card sets include two items of each object or action picture. All participants take turns in making verbal requests. There will be 5 daily sessions (3 hours per session) for two weeks.
Study NCT03629665 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Intensive Language-Action Therapy (ILAT)
Description: ILAT includes communicative language games played in an interactive small-group setting. Three persons with aphasia and one therapist sit around a table and have picture cards in front of them. The card sets include two items of each object or action picture. All participants take turns in making verbal requests. There will be 5 daily sessions (3 hours per session) for two weeks.
Study NCT03629665 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive navigated Transcranial Magnetic Stimulation during naming training
Description: Magnetic stimulation will delivered with a figure-of-eight cooled coil of Navigated Brain Stimulation System during picture naming training. The primary targeted area is the right pars triangularis. In each session, rTMS will be applied at 1-Hz for 20 minutes, 5 daily sessions per week for four weeks.
Study NCT02066948 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Meal Pattern
Description: Even or skewed distribution of protein for a 16 week period of wt loss.
Study NCT03844672 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low Power
Description: Participants will receive a low power e-cigarette to use for 3 weeks
Study NCT03844672 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Power
Description: Participants will receive a high power e-cigarette to use for 3 weeks
Study NCT03844672 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low Concentration
Description: Participants will receive a low concentration e-liquid to use for 3 weeks
Study NCT03844672 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Concentration
Description: Participants will receive a high concentration e-liquid to use for 3 weeks
Study NCT00488566 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Placebo
Study NCT00488566 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Lamictal
Description: Positive control
Study NCT04989842 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Curriculum Hannover
Description: The methodology uses a natural variation design within the Dr. Becker Clinical Group. The interventions consist of a face-to-face or a digital psychosomatic aftercare basing upon the concept of the Curriculum Hanover. A control group is included that does not receive these two interventions (but receives a similar rehabilitation treatment to the intervention groups).
Study NCT01023698 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laser photocoagulation
Description: Laser photocoagulation
Study NCT01579318 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tavokinogene Telseplasmid (tavo)
Description: Patients received intratumoral injection(s) of tavo.
Study NCT01579318 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OncoSec Medical System (OMS)
Description: Electroporation via OMS was performed immediately following intratumoral injection of tavo. A sterile applicator containing 6 stainless steel electrodes arranged in a circle were placed around the tumor. The applicator was connected to the OMS power supply and six pulseswere administered to each tumor lesion at the approximate point of tavo injection.
Study NCT02347332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinflunine
Study NCT02347332 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Study NCT02432066 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GTS-21
Description: GTS-21 is a partial alpha7 nicotinic agonist. GTS-21 will be compounded by the UF investigational pharmacy, and administered orally.
Study NCT02432066 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral placebo pills, compounded by the UF investigational pharmacy
Study NCT04082507 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Serum alpha-fetoproteine
Description: Midtrimesteric serum alpha-fetoprotein mesurment with 2D US and 3D power Doppler with MS US scan .
Study NCT03387826 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor 60 mg
Description: Ticagrelor 60 mg twice daily
Study NCT03387826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor 60 mg
Description: Ticagrelor 60 mg twice daily
Study NCT02105168 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: Optional
Study NCT02105168 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tumorous biopsy
Description: Optional
Study NCT02105168 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Healthy material sample
Description: Optional
Study NCT01188785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: siG12D LODER
Description: Phase 0 - subjects diagnosed with an operable adenocarcinoma of the pancreas will have 8 siG12D LODER placed in tumor. The siG12D LODER will be placed in the subject's tumor using an EUS biopsy needle.~Phase I - subjects diagnosed with locally non-operable advanced adenocarcinoma of the pancreas. These subjects will have one of three different siG12D LODERs dose levels placed in tumor - Either 1 siG12D LODER, 2 siG12D LODERs or 8 siG12D LODERs. The siG12D LODER/s will be placed in the subject's tumor using an EUS biopsy needle.
Study NCT06410729 — intervention group
Intervention type: OTHER
Intervention: Observational study, no intervention
Study NCT05202184 — intervention group
Intervention type: PROCEDURE
Intervention: Percutaneous thermal ablation
Description: All thermoablation procedures were performed percutaneously under ultrasound and/or CT guidance
Study NCT01551628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human arginase 1 Peg5000
Description: Patients will receive weekly IV infusions of PEG-BCT-100, until evidence of disease progression, intolerable adverse events, or withdrawal of patient consent. For safety sake, each subject will receive an induction dose of PEG-BCT-100 500 U/kg and 1000 U/kg at week -2 and week -1, respectively. The study dose of PEG-BCT-100 1600 U/kg will be initiated at week 1 (Day1). Each escalation of dose level will be determined by the investigator according to each subject's tolerability and criteria for treatment discontinuation.
Study NCT01430910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAZ104
Description: IV infusion
Study NCT01430910 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Avibactam
Description: IV infusion
Study NCT01430910 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ceftazidime
Description: IV infusion
Study NCT04366089 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oxygen-ozone therapy, probiotic supplementation and Standard of care
Description: - systemic autohemotherapy with Ozone 30 mcg / ml 250ml 2 times / day for 7 days
Study NCT01308671 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Counseling and psychosocial support
Description: Blank group will receive the same counseling and psychosocial support as varenicline group
Study NCT00880828 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FIR cervical collar with Acetaminophen
Description: FIR cervical collar with Acetaminophen QID/PRN for 4 weeks
Study NCT04366089 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: SivoMixx (200 billion)
Description: Composition of SivoMixx: Streptococcus thermophilus DSM322245, Bifidobacterium lactis DSM 32246, Bifidobacterium lactis DSM 32247, Lactobacillus acidophilus DSM 32241, Lactobacillus helveticus DSM 32242, Lactobacillus paracasei DSM 32243, Lactobacillus plantarum DSM 32244, Lactobacillus brevis DSM 27961 (NB: DSM n°... : bacterial strain identification code)
Study NCT04366089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: dose: 500mg 1 cp / day (alternatively lopinavir/ritonavir cps 200/50 mg, 2 cps x 2 / day or darunavir 800 mg 1 cp / day + ritonavir 100 mg 1 cp / day or darunavir/cobicistat 800/150 mg 1 cp / day)
Study NCT04366089 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: dose: 500mg 1 cp / day (alternatively lopinavir/ritonavir cps 200/50 mg, 2 cps x 2 / day or darunavir 800 mg 1 cp / day + ritonavir 100 mg 1 cp / day or darunavir/cobicistat 800/150 mg 1 cp / day)
Study NCT04366089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydroxychloroquine
Description: dose: 200 mg, 1 cp x 2 / day